Lilia Rodriguez Ables, MD
General Practice · Miami, FLNPI 1770543266
Payments from drug & device makers
Across 1,590 payments — averaging $6756.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$1.4M
- AbbVie$1.3M
- Novartis$1.1M
- Chiesi USA, Inc.$796K
- Pfizer$752K
- Genentech, Inc.$740K
- plus $4.7M from 22 others
Across 13 payments — averaging $7304.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$93K
- Chiesi USA, Inc.$1K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$845
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 51 | $1,394,385 |
| AbbVie | 76 | $1,332,317 |
| Novartis | 16 | $1,055,141 |
| Chiesi USA, Inc. | 350 | $795,653 |
| Pfizer | 358 | $752,455 |
| Genentech, Inc. | 143 | $740,403 |
| Avanir Pharmaceuticals, Inc. | 93 | $736,291 |
| Eli Lilly | 14 | $735,554 |
| E.r. Squibb & Sons, L.L.C. | 4 | $660,363 |
| Sanofi US Services Inc. | 104 | $459,017 |
| Janssen Research & Development, LLC | 116 | $324,192 |
| Teva Pharmaceuticals USA, Inc. | 91 | $277,716 |
| Ionis Pharmaceuticals, Inc. | 48 | $275,151 |
| Biogen | 2 | $221,496 |
| Boehringer Ingelheim | 32 | $208,801 |
| AstraZeneca | 7 | $202,528 |
| Amgen | 5 | $179,572 |
| C. R. Bard, Inc. & Subsidiaries | 4 | $147,986 |
| GRT US Holding, Inc. | 17 | $95,807 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $59,182 |
| VYNE Pharmaceuticals Inc. | 19 | $38,870 |
| Lexicon Pharmaceuticals, Inc. | 1 | $34,053 |
| Dermavant Sciences, Inc. | 6 | $8,000 |
| Kowa Research Institute, Inc. | 3 | $3,262 |
| Boehringer Ingelheim International GmbH | 12 | $2,116 |
| Boehringer Ingelheim Canada Ltd.ltee | 9 | $1,206 |
| Genentech USA, Inc. | 3 | $859 |
| GSK | 1 | $18 |
How this compares
$10,742,394 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other general practice in Miami
- Jose CardonaMiami$71M
- Armando AcevedoMiami$15.2M
- Jorge AmayaMiami$14.2M
- Hector RodriguezMiami$12.8M
- Idalia AcostaMiami$11.4M
- Omar BenitezMiami$6.9M
- Sara LlerenaMiami$6.3M
- Ana AcostaMiami$6.3M
- Gil Fernandez-YeraMiami$4.9M
- Manuel FernandezMiami$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.